Program Chair
Claudio Anasetti, MD
Professor, Departments of Medicine and Interdisciplinary Oncology
University of South Florida, College of Medicine
Chief, Division of Blood and Marrow Transplantation
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Program Faculty
Edwin P. Alyea III, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Director, Stem Cell Transplant Program
Dana-Farber Cancer Institute/Brigham and Women’s Hospital
Boston, Massachusetts
Charles A. Linker, MD
Clinical Professor of Medicine
Director, Adult Leukemia & Bone Marrow Transplant Program
University of California, San Francisco
San Francisco, California
Expired
Program Overview
Hematopoietic stem cell transplantation (HSCT) remains a potentially curative treatment approach for many patients with hematologic malignancies. HSCT strategies are continually evolving to reduce the impact of adverse effects and to enhance graft-versus-leukemia effects. Strategies include the development of standard myeloablative preparative regimens using targeted and novel agents to enhance drug exposure with minimal increases in toxicity. Another strategy under investigation includes reduced-intensity conditioning regimens to facilitate the use of HSCT as a treatment option for patients who may otherwise be contraindicated for traditional myeloablative regimens. This CME activity will review current investigations of the myeloablative and nonmyeloablative preparative regimens used to minimize complications and adverse events, to minimize disease relapse, and to enhance long-term survival for patients with hematologic malignancies undergoing HSCT.
Target Audience
This activity is designed to meet the educational needs of hematologist-oncologists and other health care professionals involved in blood and bone marrow transplantation.
Learning Objectives
At the conclusion of this educational activity, participants should be better able to:
• Discuss strategies to enhance efficacy and reduce toxicity of fully ablative conditioning regimens for HSCT in patients with hematologic malignancies
• Evaluate the efficacy and safety of nonmyeloablative conditioning regimens for HSCT
• Describe autologous HSCT strategies to minimize relapse in patients with acute myeloid leukemia
Accreditation Statement
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit Statement
The Medical College of Wisconsin designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosure
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. A relevant financial relationship is one in any amount that has occurred in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Edwin P. Alyea III, MD has disclosed no relevant financial relationships.
Claudio Anasetti, MD has disclosed the following relevant financial relationships: Consultant, Research Support PDL BioPharma, Inc.
Denise C. LaTemple, PhD, Vice President, Scientific Services, Curatio CME Institute, has disclosed no relevant financial relationships.
Charles A. Linker, MD has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, Curatio CME Institute, has disclosed no relevant financial relationships.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Privacy & Confidentiality Statement
Carden Jennings Publishing Co., Ltd., the publisher of Bloodline, does not collect or track personal information from participants in this CME activity. Generic information from server logs may be used to track and analyze the number of visits to the site, and to find out what types of browser software are used by visitors. This information will be used only in aggregate form, and used solely for improving website design and performance.
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.